कृपया अन्य खोज का प्रयास करें
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Robert Tjian | 72 | 2016 | Chairman of Scientific Advisory Board |
David Lacey | 69 | 2016 | Independent Chairman |
Arthur T. Sands | 59 | 2014 | CEO, President & Director |
Julia Paige Gregory | 69 | 2019 | Independent Director |
John Kuriyan | - | - | Founder & Member of Scientific Advisory Board |
Lori Anne Kunkel | 64 | 2019 | Independent Director |
Judith A. Reinsdorf | 58 | 2021 | Independent Director |
Paul M. Silva | 56 | 2021 | Independent Director |
Arthur Weiss | - | - | Founder & Member of Scientific Advisory Board |
Michael Rapé | - | - | Founder & Member of Scientific Advisory Board |
Ronald Levy | - | 2023 | Member of Medical Advisory Board |
Roy D. Baynes | 68 | - | Member of Medical Advisory Board |
Edward C. Saltzman | 69 | 2022 | Independent Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है